Drug Profile
Arsenic trioxide - Teva Pharmaceutical Industries
Alternative Names: NSC-706363; TrisenoxLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator CTI BioPharma
- Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
- Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute promyelocytic leukaemia
- Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Phase I/II Glioma
- Discontinued Multiple myeloma
Most Recent Events
- 26 Jun 2023 CTI BioPharma has been acquired by Swedish Orphan Biovitrum
- 05 Oct 2020 CTI Biopharma terminates a phase II trial for Myelodysplastic Syndromes in USA (IV) (NCT00020969)
- 06 Aug 2018 National Institutes of Health and Teva Pharmaceuticals terminates a phase I trial for Chronic myeloid leukaemia (second-line therapy or greater, combination thereapy) in USA (NCT01397734)